Current price is more than the intrinsic value

Intrinsic Value

Stock has been generating better return on equity than bank FD

ROE vs FD rates

Stock doesn't offer attractive dividend returns

Dividend Returns

Good time to consider, as stock is not in overbought zone

Entry Point

Stock not in ASM/GSM lists and not a lot of promoter holding is pledged

No Red Flags

An upcoming facility in Indore will cater to domestic and global markets

Gufic Biosciences to invest ₹240 crore in new units

Contributing immensely to the government’s ambitious Make in India drive, Gufic has collaborated with its European counterpart to manufacture this new technology indigenously in India. Until now the dual chamber bags have been largely imported in

Gufic Biosciences launches indigenously produced Dual Chamber Bags

Rating agency CRISIL Ratings has revised the company’s outlook on the long-term bank facilities

Gufic Biosciences soars 14%, hits 52-week high on improved business outlook

Gufic Biosciences rose 1.58% to Rs 263.05 after the company received the DCGI approval for Thymosin Alpha-1 (Immunocin α) as an add-on therapy for the treatment of moderate-to-severe COVID-19 patients requiring ventilator support.

Gufic Biosciences gains on DCGA nod for Thymosin Alpha-1

Buzzing stocks: Tata Steel, TCS, Tata Power, TVS Motor, Marico, U Gro Capital, Sejal Glass, Gufic Biosciences, Rain Industries, PSP Projects and Coastal Corp

Stocks that will see action today

Gufic Biosciences incorporates wholly-owned subsidiary in UK

Stocks In the News: Check out the companies making headlines before the opening bell.

Buzzing Stocks | BEML, Gufic Biosciences, Satin Creditcare Network, others in news today

Check out the stocks that will be in focus during trade today based on recent and latest news developments.

Top stocks in focus: PNB Housing Finance, Biocon, Gufic Biosciences, NTPC, Bharti Airtel

Gufic Biosciences added 3.32% to Rs 230.3 after the pharmaceutical company announced that it is entering into a research and collaboration agreement with Selvax Pty to accelerate the commercialization of Selvax’s cancer immunotherapy treatment.

Gufic Biosciences rises after signing research and collaboration agreement with Selvax

Stocks to Watch: Bharti Airtel, Tata Power, Zydus Lifesciences, Lara Supergenerics, Vakrangee, PNB Housing Fin, Gufic Biosciences,kKalapana Ind, Brightcom group, IIFL Wealth

Stocks to watch today (March 10)

To accelerate commercialization of Selvax’s cancer immunotherapy treatment

Gufic Biosciences enters into research and collaboration agreement with Australia based Selvax

Gufic Biosciences Limited manufactures pharmaceuticals, medicinal chemicals and botanical products. The Company's segments include Formulations, Bulk Drugs and Consumer.

Gufic Biosciences Ltd

Gufic Biosciences Ltd

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Gufic Biosciences to invest ₹240 crore in new units

Gufic Biosciences launches indigenously produced Dual Chamber Bags

Gufic Biosciences soars 14%, hits 52-week high on improved business outlook

Gufic Biosciences gains on DCGA nod for Thymosin Alpha-1

Stocks that will see action today

Gufic Biosciences incorporates wholly-owned subsidiary in UK

Buzzing Stocks | BEML, Gufic Biosciences, Satin Creditcare Network, others in news today

Gufic Biosciences Ltd

Intrinsic ValueIntrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD ratesFixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend ReturnsA dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry PointHigh demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock

News & Opinions

Gufic Biosciences to invest ₹240 crore in new units

Gufic Biosciences launches indigenously produced Dual Chamber Bags

Gufic Biosciences soars 14%, hits 52-week high on improved business outlook

Gufic Biosciences gains on DCGA nod for Thymosin Alpha-1

Stocks that will see action today

Gufic Biosciences incorporates wholly-owned subsidiary in UK

Buzzing Stocks | BEML, Gufic Biosciences, Satin Creditcare Network, others in news today

Intrinsic Value
Intrinsic value is the calculated value of the company and may differ from current stock price. If intrinsic value > current price, price increase is expected in the future to reduce the gap and vice-versa

ROE vs FD rates
Fixed Deposit rate is a virtually risk-free rate where the investor assumes almost no risk on their investment. If stock's long term average ROE is lower than this rate, investors are better off investing the amount in a FD

Dividend Returns
A dividend is the distribution of reward from a portion of company's earnings and is paid to its shareholders. Good dividend returns indicate good health and outlook for the company

Entry Point
High demand for a stock increases its price. If the price is pushed up to a level which is not justified, then it's considered to be in the overbought zone, which is not a good time to buy the stock